Latest News

everlinQ endoAVF receives FDA de novo marketing approval

everlinQ endoAVF System (TVA Medical) is now approved by the US Food and Drug Administration for de novo marketing. This innovative, minimally invasive technology...


Combined carotid and coronary revascularisation: Is this a good idea?

George Chrysant gives an overview of combined revascularisation interventions for coronary and carotid disease, arguing that "carotid artery stenting and coronary artery bypass grafting...

Deficiencies in operator behaviour: Premature atypical malignancies in high-volume operators

In this article, Bijan Modarai outlines recent research on the effects of radiation exposure in high-volume interventionalists, why a future with alternative modalities to...


Marc Schermerhorn (Boston, USA) discusses the three-year results of an analysis on the long-term survival of Nellix EVAS system (Endologix) IDE trial patients vs. a cohort of EVAR patients. The study found that EVAS is associated with higher long-term...


Michael Edmonds

Stephan Haulon

Stéphan Haulon

Thomas Schmitz-Rixen

(Visited 40,564 times, 75 visits today)